V. A. Miller

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +14

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients

Ilya G. Serebriiskii, Caitlin Connelly, Garrett M. Frampton et al. · Nature Communications · 2019 · 213 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

Y. Y. Janjigian, Harry J.M. Groen, Leora Horn et al. · Journal of Clinical Oncology · 2011 · 144 citations

Medicine, Oncology, Pharmacology +17

<i>ALK</i>Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy

Jeffrey S. Ross, Siraj M. Ali, Omotayo Fasan et al. · The Oncologist · 2017 · 133 citations · Full text

Medicine, Molecular Genetics, Oncology +12

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)

Vera Hirsh, J. Cadranel, Xiuyu Julie Cong et al. · Journal of Thoracic Oncology · 2013 · 78 citations · Full text

Medicine, Oncology, Pharmacology +8